107 Kodiak Sciences Inc. Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) (in thousands, except share and per share amounts) Redeemable Convertible Preferred Stock Common Stock Additional Paid-In Accumulated Total Stockholders’ Equity Shares Amount Shares Amount Capital Deficit (Deficit) Balances at January 1, 2016........................... 12,385,154 $ 50,017 7,828,908 $ 1 $ 18 $ (24,255) $ (24,236) Issuance of common stock upon exercise of stock options ..................................... — — 10,674 — 5 — 5 Vesting of early exercised stock options.......................................... — — — — 12 — 12 Issuance of restricted stock awards.......... — — 142,938 — — — — Repurchase of early exercised stock options.......................................... — — (51,689) — (4) — (4) Stock-based compensation expense......... — — — — 272 — 272 Net loss..................................................... — — — — — (17,132) (17,132) Balances at December 31, 2016..................... 12,385,154 50,017 7,930,831 1 303 (41,387) (41,083) Issuance of common stock upon exercise of stock options ..................................... — — 5,603 — 3 — 3 Vesting of early exercised stock options.......................................... — — — — 3 — 3 Stock-based compensation expense......... — — — — 275 — 275 Net loss..................................................... — — — — — (27,936) (27,936) Balances at December 31, 2017..................... 12,385,154 50,017 7,936,434 1 584 (69,323) (68,738) Issuance of common stock upon exercise of stock options ..................................... — — 47,800 — 49 — 49 Issuance of restricted stock awards.......... — — 27,500 — — — — Conversion of redeemable convertible preferred stock into common stock....... (12,385,154) (50,017) 12,385,154 1 50,016 — 50,017 Conversion of redeemable convertible preferred stock warrants into common stock warrants......................... — — — — 5,000 — 5,000 Issuance of common stock upon exercise of common stock warrants .................... — — 100,000 — — — — Conversion of 2017 and 2018 convertible notes into common stock....................... — — 6,932,969 1 55,732 — 55,733 Issuance of common stock upon initial public offering, net of issuance cost of $10,542...................................... — — 9,400,000 1 83,458 — 83,459 Stock-based compensation expense......... — — — — 2,756 — 2,756 Net loss..................................................... — — — — — (41,443) (41,443) Balances at December 31, 2018..................... — $ — 36,829,857 $ 4 $ 197,595 $ (110,766) $ 86,833 The accompanying notes are an integral part of these consolidated financial statements.